The noninvasive fibrosis-4 index can further refine the existing favorable clinical profile for hepatocellular carcinoma risk in noncirrhotic patients with chronic hepatitis B virus infection and help identify those with the lowest risk, say researchers.
Serum hepatitis B virus RNA levels correlate with viral transcriptional activity and histologic changes in the livers of patients with chronic HBV who are receiving nucleos(t)ide analog therapy, Chinese researchers report.
Most patients with chronic hepatitis B virus infection initially classed as partial responders to treatment with tenofovir disoproxil fumarate achieve a virologic response without additional treatment adjustment, research suggests.
Being in the immune tolerant phase of chronic hepatitis B virus (HBV) infection is no assurance against the risk for developing hepatocellular carcinoma (HCC), requiring liver transplantation, or dying, say South Korean investigators.
A panel of hepatitis B virus experts has issued a consensus statement intended to aid in standardizing the efficacy and safety appraisals of novel, potentially curative antiviral and immune modulatory agents.
Two research groups have developed noninvasive indices to detect significant fibrosis in treatment-naïve patients with chronic hepatitis B virus infection, one using serum levels of Golgi protein 73 and liver stiffness, and the other based on the ratio of gamma-glutamyl transpeptidase to albumin.
Achieving hepatitis B surface antigen seroclearance neutralizes the increased risk for hepatitis B virus-related hepatocellular carcinoma among women aged 50 years or younger, but not among older women or men regardless of their age, research indicates.
Achieving a subcirrhotic liver stiffness level after antiviral therapy halves the risk for hepatocellular carcinoma in patients with chronic hepatitis B virus-related advanced fibrosis or cirrhosis, Korean research shows.
The Japanese nationwide selective vaccination strategy has led to a substantial reduction in perinatal hepatitis B virus transmission, say researchers who evaluated the prevalence of hepatitis B surface antigen among pregnant women born before and after its implementation.
A high burden of metabolic risk factors significantly increases the risk for hepatocellular carcinoma among men with hepatitis B virus infection, particularly those who smoke, researchers from Taiwan report.
In patients with persistently low serum levels of hepatitis B virus DNA, the combined use of the noninvasive aspartate aminotransferase to platelet ratio index and the Fibrosis-4 index could help identify those at increased risk for developing hepatocellular carcinoma.
The incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection declines significantly after the first 5 years of treatment with the nucleos(t)ide analogs entecavir and/or tenofovir, researchers report.
Analysis of a community-based cohort comprising mainly Asian patients receiving antiviral therapy for chronic hepatitis B virus infection shows a higher rate of hepatitis B surface antigen loss than is generally reported for Asian clinical trial cohorts.
Serum hepatitis B core antibody levels significantly predict hepatic inflammation in patients with chronic hepatitis B virus infection, including those with normal alanine aminotransferase levels, Chinese research shows.